Olfactory dysfunction in Parkinson's disease
Olfactory dysfunction in Parkinson's disease
复制标题
DOI：
10.1159/000109757
复制
发表时间：
2008-01-01
期刊：
影响因子：
--
通讯作者：
Duda, John E.
中科院分区：
文献类型：
--
作者：
Kranick, Sarah M.;Duda, John E.
在特发性帕金森病（PD）的主要运动特征发作之前，神经变性的其他表现，如嗅觉功能障碍通常是明显的。表征临床前PD的这些潜在生物标志物对于识别将继续发展致残症状的个体特别重要，因此是新神经保护策略的良好候选人。如Braak PD神经病理分期所示，嗅觉系统是最早显示路易体病理的神经元群体之一。在临床上，嗅觉丧失可以很容易地在办公室使用几种经过验证的技术进行测试，并且通常有助于医生区分特发性PD和其他形式的帕金森病。最近的研究结果表明，在选定的高危患者中可以观察到嗅觉下降，这对确定潜在的研究人群具有重要意义。正在进行的嗅觉功能障碍研究也可能揭示，除了用作PD诊断的生物标志物外，还可能用作疾病进展的药物独立生物标志物。版权所有（c）2008 S. Karger AG，巴塞尔。
Prior to the onset of the cardinal motor features of idiopathic Parkinson's disease (PD), other manifestations of neurodegeneration such as olfactory dysfunction are often apparent. Characterizing these potential biomarkers of preclinical PD is particularly important in identifying individuals who will go on to develop disabling symptoms, and thus be good candidates for new neuroprotective strategies. As shown by the Braak neuropathologic staging of PD, the olfactory system is among the first neuronal populations to display Lewy body pathology. Clinically, loss of smell can be easily tested in the office using several validated techniques and is often helpful to the physician in distinguishing idiopathic PD from other forms of parkinsonism. Recent findings have indicated that a decline in olfaction may be observed in selected at-risk patients, which has significant implications for identifying potential study populations. Ongoing studies of olfactory dysfunction may also reveal potential for use as a medication-independent biomarker of disease progression in addition to use as a biomarker for the diagnosis of PD. Copyright (c) 2008 S. Karger AG, Basel.